Ginkgo Bioworks (DNA) Competitors $12.67 +1.31 (+11.53%) Closing price 03:59 PM EasternExtended Trading$12.44 -0.23 (-1.85%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. DNLI, RXRX, BLTE, CGON, INDV, AGIO, APGE, IDYA, SRPT, and HRMYShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Denali Therapeutics (DNLI), Recursion Pharmaceuticals (RXRX), Belite Bio (BLTE), CG Oncology (CGON), Indivior (INDV), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), IDEAYA Biosciences (IDYA), Sarepta Therapeutics (SRPT), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Its Competitors Denali Therapeutics Recursion Pharmaceuticals Belite Bio CG Oncology Indivior Agios Pharmaceuticals Apogee Therapeutics IDEAYA Biosciences Sarepta Therapeutics Harmony Biosciences Denali Therapeutics (NASDAQ:DNLI) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Which has better valuation & earnings, DNLI or DNA? Denali Therapeutics has higher revenue and earnings than Ginkgo Bioworks. Denali Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M6.55-$422.77M-$2.67-5.58Ginkgo Bioworks$227.04M3.27-$547.03M-$9.16-1.38 Does the media prefer DNLI or DNA? In the previous week, Denali Therapeutics and Denali Therapeutics both had 3 articles in the media. Denali Therapeutics' average media sentiment score of 0.99 beat Ginkgo Bioworks' score of 0.48 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is DNLI or DNA more profitable? Denali Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -198.84%. Denali Therapeutics' return on equity of -35.90% beat Ginkgo Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -35.90% -32.41% Ginkgo Bioworks -198.84%-52.35%-27.14% Do analysts recommend DNLI or DNA? Denali Therapeutics presently has a consensus price target of $33.71, indicating a potential upside of 126.27%. Ginkgo Bioworks has a consensus price target of $5.77, indicating a potential downside of 54.49%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Denali Therapeutics is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06Ginkgo Bioworks 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Do insiders and institutionals believe in DNLI or DNA? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, DNLI or DNA? Denali Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. SummaryDenali Therapeutics beats Ginkgo Bioworks on 13 of the 16 factors compared between the two stocks. Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksMED IndustryMedical SectorNYSE ExchangeMarket Cap$741.58M$2.90B$5.49B$20.51BDividend YieldN/A2.69%5.38%3.76%P/E Ratio-1.3821.2626.2027.81Price / Sales3.27279.34415.5037.44Price / CashN/A41.8936.4921.79Price / Book0.967.508.054.55Net Income-$547.03M-$55.05M$3.15B$984.47M7 Day Performance35.80%2.49%1.92%3.57%1 Month Performance78.15%7.40%4.90%6.03%1 Year PerformanceN/A5.42%35.95%14.48% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks0.8177 of 5 stars$12.67+11.5%$5.77-54.5%N/A$741.58M$227.04M-1.38640DNLIDenali Therapeutics4.5584 of 5 stars$13.62-1.9%$33.71+147.5%-36.6%$1.98B$330.53M-5.10430News CoverageRXRXRecursion Pharmaceuticals2.0492 of 5 stars$4.83-4.0%$7.00+44.9%-31.2%$1.96B$58.84M-2.73400BLTEBelite Bio2.6647 of 5 stars$61.50+1.7%$96.67+57.2%+24.7%$1.96BN/A-45.2210CGONCG Oncology2.7236 of 5 stars$25.66+0.4%$58.67+128.6%-16.9%$1.96B$1.14M-16.9961INDVIndivior2.9527 of 5 stars$13.95-0.4%$15.00+7.5%-6.9%$1.93B$1.19B-45.001,051News CoverageAnalyst ForecastAGIOAgios Pharmaceuticals4.0473 of 5 stars$33.34-3.1%$58.60+75.8%-20.8%$1.93B$36.50M2.97390APGEApogee Therapeutics2.7112 of 5 stars$41.35-1.5%$94.60+128.8%+14.7%$1.90BN/A-11.4991Analyst ForecastIDYAIDEAYA Biosciences3.6457 of 5 stars$21.42-1.2%$54.27+153.4%-41.2%$1.88B$7M-5.9780SRPTSarepta Therapeutics4.7282 of 5 stars$18.87-6.0%$67.64+258.5%-88.7%$1.85B$1.90B-7.011,372High Trading VolumeHRMYHarmony Biosciences4.8267 of 5 stars$31.93+0.1%$53.63+67.9%+5.3%$1.83B$714.73M12.19200Positive News Related Companies and Tools Related Companies Denali Therapeutics Competitors Recursion Pharmaceuticals Competitors Belite Bio Competitors CG Oncology Competitors Indivior Competitors Agios Pharmaceuticals Competitors Apogee Therapeutics Competitors IDEAYA Biosciences Competitors Sarepta Therapeutics Competitors Harmony Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
